Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.

@article{Koh2013TreatmentOR,
  title={Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.},
  author={Won Jung Koh and Goohyeon Hong and Su-Young Kim and Byeong-Ho Jeong and Hye Yoon Park and Kyeongman Jeon and O Jung Kwon and Seung-Heon Lee and Chang Ki Kim and Sung Jae Shin},
  journal={Antimicrobial agents and chemotherapy},
  year={2013},
  volume={57 5},
  pages={2281-5}
}
Moxifloxacin (MXF) has in vitro and in vivo activity against Mycobacterium avium complex (MAC) in experimental models. However, no data are available concerning its treatment effect in patients with MAC lung disease. The aim of this study was to evaluate the clinical efficacy of an MXF-containing regimen for the treatment of refractory MAC lung disease. Patients with MAC lung disease who were diagnosed between January 2002 and December 2011 were identified from our hospital database. We… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…